- Home
- ELAB vs ENVB Comparison
ELAB vs ENVB Comparison
Compare ELAB & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- ENVB
- Stock Information
- Founded
- ELAB 2020
- ENVB 1994
- Country
- ELAB United States
- ENVB United States
- Employees
- ELAB N/A
- ENVB N/A
- Industry
- ELAB
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- ENVB Health Care
- Exchange
- ELAB Nasdaq
- ENVB Nasdaq
- Market Cap
- ELAB 3.2M
- ENVB 3.0M
- IPO Year
- ELAB 2023
- ENVB N/A
- Fundamental
- Price
- ELAB $4.78
- ENVB $0.97
- Analyst Decision
- ELAB
- ENVB Strong Buy
- Analyst Count
- ELAB 0
- ENVB 1
- Target Price
- ELAB N/A
- ENVB $10.00
- AVG Volume (30 Days)
- ELAB 2.4M
- ENVB 326.4K
- Earning Date
- ELAB 11-13-2025
- ENVB 11-13-2025
- Dividend Yield
- ELAB N/A
- ENVB N/A
- EPS Growth
- ELAB N/A
- ENVB N/A
- EPS
- ELAB N/A
- ENVB N/A
- Revenue
- ELAB N/A
- ENVB N/A
- Revenue This Year
- ELAB N/A
- ENVB N/A
- Revenue Next Year
- ELAB N/A
- ENVB N/A
- P/E Ratio
- ELAB N/A
- ENVB N/A
- Revenue Growth
- ELAB N/A
- ENVB N/A
- 52 Week Low
- ELAB $4.29
- ENVB $0.85
- 52 Week High
- ELAB $1,842.11
- ENVB $8.33
- Technical
- Relative Strength Index (RSI)
- ELAB 36.26
- ENVB 40.51
- Support Level
- ELAB $4.29
- ENVB $0.85
- Resistance Level
- ELAB $4.89
- ENVB $1.06
- Average True Range (ATR)
- ELAB 0.60
- ENVB 0.10
- MACD
- ELAB -0.09
- ENVB -0.02
- Stochastic Oscillator
- ELAB 12.50
- ENVB 19.34
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.